Literature DB >> 7948429

Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms.

F Björnberg1, M Lantz, I Olsson, U Gullberg.   

Abstract

The two tumor necrosis factor (TNF) receptors (TNF-R55 and TNF-R75) can release soluble TNF-binding proteins (TNF-R55-BP and TNF-R75-BP) by proteolytic cleavage. The proteolytic processing of the TNF receptors was investigated in monoblastic THP-1 and promyelocytic HL-60-10 leukemic cell lines. The release of soluble forms of both receptors was rapidly stimulated by staurosporine-sensitive protein kinase C activation by phorbol myristate acetate (PMA) and more slowly stimulated by TNF. No receptor release was seen below a temperature of 16 degrees C. NH4Cl (10 mmol/liter) and monensin (1 mumol/liter), known to increase intracellular pH, inhibited to some extent PMA- and TNF-induced release of both TNF-R55-BP and TNF-R75-BP. The inhibitory effect of monensin might be explained by a diminished translocation of newly synthesized receptor to the plasma membrane. The weak inhibitory effect of NH4Cl on PMA-induced release of soluble receptor forms could be due to effects on a pH-sensitive compartment. PMA-induced down-regulation of receptors was not dependent on acidity as it occurred also in the presence of monensin and NH4Cl when the release of TNF-BPs is partially blocked. Dibutyryl cAMP inhibited the PMA-induced release of TNF-R55-BP but not of TNF-R75-BP in both cell lines investigated. In addition, dibutyryl cAMP alone stimulated the release of both receptors but only in THP-1 cells. Our data show that the generation of soluble forms of both TNF receptors can be regulated by both PKC and PKA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7948429

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  10 in total

1.  Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP.

Authors:  D Vial; L Arbibe; N Havet; C Dumarey; B Vargaftig; L Touqui
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

2.  Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infection.

Authors:  M Weiss; M Martignoni; T Petropoulou; B Sölder; B H Belohradsky
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

3.  Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2.

Authors:  Patric Lundberg; Paula V Welander; Carl K Edwards; Nico van Rooijen; Edouard Cantin
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

4.  Isolation of viable antigen-specific CD8+ T cells based on membrane-bound tumor necrosis factor (TNF)-α expression.

Authors:  Danielle Haney; Máire F Quigley; Tedi E Asher; David R Ambrozak; Emma Gostick; David A Price; Daniel C Douek; Michael R Betts
Journal:  J Immunol Methods       Date:  2011-04-08       Impact factor: 2.303

5.  Interleukin-10 modulates proinflammatory cytokines in the human monocytic cell line THP-1 stimulated with Borrelia burgdorferi lipoproteins.

Authors:  P K Murthy; V A Dennis; B L Lasater; M T Philipp
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

6.  Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA.

Authors:  P Neuner; M Pourmojib; G Klosner; F Trautinger; R Knobler
Journal:  Arch Dermatol Res       Date:  1996-10       Impact factor: 3.017

7.  Bone structural effects of variation in the TNFRSF1B gene encoding the tumor necrosis factor receptor 2.

Authors:  B H Mullin; R L Prince; I M Dick; F M A Islam; D J Hart; T D Spector; A Devine; F Dudbridge; S G Wilson
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

8.  CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis.

Authors:  Maria K Magnusson; Rahil Dahlén; Hans Strid; Stefan Isaksson; Magnus Simrén; Anders Lasson; Antal Bajor; Kjell-Arne Ung; Lena Ohman
Journal:  United European Gastroenterol J       Date:  2013-12       Impact factor: 4.623

9.  Construction and characterization of a transmembrane eukaryotic expression vector based on the membrane domain structure of TNF-α.

Authors:  Fa Wang; Liang Zeng; Yue-Li Wang; Shi-Quan Cui; Liang Hu; Jun-Ming Zheng; Di-Nan Huang; Gan Hou
Journal:  Mol Med Rep       Date:  2017-06-06       Impact factor: 2.952

10.  Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle.

Authors:  Chun Hou; Yong Miao; Xue Wang; Chaoyue Chen; Bojie Lin; Zhiqi Hu
Journal:  Exp Ther Med       Date:  2016-05-09       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.